[Federal Register Volume 60, Number 144 (Thursday, July 27, 1995)]
[Notices]
[Pages 38576-38577]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-18407]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[DEA #134P]
Controlled Substances: Proposed Aggregate Production Quotas for
1996
AGENCY: Drug Enforcement Administration (DEA), Justice.
ACTION: Notice of proposed aggregate production quotas for 1996.
-----------------------------------------------------------------------
SUMMARY: This notice proposes initial 1996 aggregate production quotas
for controlled substances in Schedules I and II of the Controlled
Substances Act.
DATES: Comments or objections should be received on or before August
28, 1995.
ADDRESSES: Send comments or objections to the Deputy Administrator,
Drug Enforcement Administration, Washington, DC 20537, Attn: DEA
Federal Register Representative (CCR).
FOR FURTHER INFORMATION CONTACT:
Howard McClain, Jr., Chief, Drug & Chemical Evaluation Section, Drug
Enforcement Administration, Washington, D.C. 20537, Telephone: (202)
307-7183.
SUPPLEMENTARY INFORMATION: Section 306 of the Controlled Substances Act
(21 U.S.C. 826) requires that the Attorney General establish aggregate
production quotas for each basic class of controlled substance listed
in Schedules I and II. This responsibility has been delegated to the
Administrator of the DEA by Section 0.100 of Title 28 of the Code of
Federal Regulations.
The Administrator, in turn, has redelegated this function to the
Deputy Administrator pursuant to Sec. 0.104 of Title 28 of the Code of
Federal Regulations.
The quotas are to provide adequate supplies of each substance for:
(1) The estimated medical, scientific, research, and industrial needs
of the United States; (2) lawful export requirements; and (3) the
establishment and maintenance of reserve stocks.
In determining the below listed proposed 1996 aggregate production
quotas, the Deputy Administrator considered the following factors: (1)
Total actual 1994 and estimated 1995 and 1996 net disposals of each
substance by all manufacturers; (2) estimates of 1995 year-end
inventories of each substance and of any substance manufactured from it
and trends in accumulation of such inventories; and (3) projected
demand as indicated by procurement quota applications filed pursuant to
Sec. 1303.12 of title 21 of the Code of Federal Regulations.
Pursuant to Sec. 1303.23(c) of title 21 of the Code of Federal
Regulations, the Deputy Administrator of the DEA will, in early 1996,
adjust aggregate production quotas and individual manufacturing quotas
allocated for the year based upon 1995 year-end inventory and actual
1995 disposition data supplied by quota recipients for each basic class
of Schedule I or II controlled substance.
Therefore, under the authority vested in the Attorney General by
section 306 of the Controlled Substances Act of 1970 (21 U.S.C. 826),
delegated to the Administrator of the DEA by Sec. 0.100 of title 28 of
the Code of Federal Regulations, and redelegated to the Deputy
Administrator pursuant to Sec. 0.104 of title 28 of the Code of Federal
Regulations, the Deputy Administrator hereby proposes that the
aggregate production quotas for 1996 for the following controlled
substances, expressed in grams of anhydrous acid or base, be
established as follows:
------------------------------------------------------------------------
Proposed
Basic class 1996 quotas
------------------------------------------------------------------------
Schedule I:
Acetylmethadol........................................... 7
Alphacetylmethadol....................................... 7
Aminorex................................................. 7
Cathinone................................................ 9
Difenoxin................................................ 14,000
Dihydromorphine.......................................... 7
2,5-Dimethoxyamphetamine................................. 10,650,000
Dimethylamphetamine...................................... 7
Ethylamine Analog of Phencyclidine....................... 5
N-Ethylamphetamine....................................... 7
Lysergic acid diethylamide............................... 58
Mescaline................................................ 7
Methaqualone............................................. 17
Methcathinone............................................ 9
4-Methoxyamphetamine..................................... 17
4-Methylaminorex......................................... 2
3,4-Methylenedioxyamphetamine............................ 17
3,4-Methylenedioxy-N-ethylamphetamine.................... 27
3,4-Methylenedioxymethamphetamine........................ 42
3-Methylfentanyl......................................... 14
[[Page 38577]]
Normethadone............................................. 7
Normorphine.............................................. 7
Psilocybin............................................... 2
Psilocyn................................................. 2
Tetrahydrocannibinols.................................... 55,100
Schedule II:
Alfentanil............................................... 8,500
Amobarbital.............................................. 15
Amphetamine.............................................. 1,300,100
Cocaine.................................................. 550,040
Codeine (for sale)....................................... 58,395,000
Codeine (for conversion)................................. 16,632,000
Desoxyephedrine, 1,000,000 grams of levodesoxyephedrine
for use in a noncontrolled, nonprescription product and
44 kg for methamphetamine............................... 1,044,000
Dextropropoxyphene....................................... 118,066,000
Dihydrocodeine........................................... 60,000
Diphenoxylate............................................ 1,063,000
Ecgonine (for conversion)................................ 650,100
Ethylmorphine............................................ 12
Fentanyl................................................. 120,100
Hydrocodone (for sale)................................... 8,880,000
Hydrocodone (for conversion)............................. 2,800,000
Hydromorphone............................................ 448,000
Isomethadone............................................. 12
Levo-alpha-acetylmethadol................................ 200,000
Levorphanol.............................................. 14,300
Meperidine............................................... 10,822,000
Methadone................................................ 4,551,000
Methadone (for conversion)............................... 364,000
Methadone Intermediate (for conversion).................. 5,534,000
Methamphetamine (for conversion)......................... 723,000
Methylphenidate.......................................... 10,291,000
Morphine (for sale)...................................... 12,450,000
Morphine (for conversion)................................ 76,735,000
Noroxymorphone (for sale)................................ 2,000
Noroxymorphone (for conversion).......................... 2,406,000
Opium.................................................... 1,226,000
Oxycodone (for sale)..................................... 5,571,000
Oxycodone (for conversion)............................... 37,300
Oxymorphone.............................................. 11,200
Pentobarbital............................................ 15,100,000
Phencyclidine............................................ 40
Phenylacetone (for conversion)........................... 5,280,000
1-Phenylcyclohexylamine.................................. 10
1-Piperidinocyclohexanecarbonitrile...................... 12
Secobarbital............................................. 400,000
Sufentanil............................................... 1,000
Thebaine................................................. 9,217,000
------------------------------------------------------------------------
The Deputy Administrator further proposes that aggregate production
quotas for all other Schedules I and II controlled substances included
in Secs. 1308.11 and 1308.12 of title 21 of the Code of Federal
Regulations be established at zero.
All interested persons are invited to submit their comments and
objections in writing regarding this proposal. A person may object to
or comment on the proposal relating to any of the above-mentioned
substances without filing comments or objections regarding the others.
If a person believes that one or more of these issues warrant a
hearing, the individual should so state and summarize the reasons for
this belief.
In the event that comments or objections to this proposal raise one
or more issues which the Deputy Administrator finds warrant a hearing,
the Deputy Administrator shall order a public hearing by notice in the
Federal Register, summarizing the issues to be heard and setting the
time for the hearing.
The Office of Management and Budget has determined that notices of
aggregate production quotas are not subject to centralized review under
Executive Order 12866. This action has been analyzed in accordance with
the principles and criteria contained in Executive Order 12612, and it
has been determined that this matter does not have sufficient
federalism implications to warrant the preparation of a Federalism
Assessment.
The Deputy Administrator hereby certifies that this action will
have no significant impact upon small entities whose interests must be
considered under the Regulatory Flexibility Act, 5 U.S.C. 601, et seq.
The establishment of annual aggregate production quotas for Schedules I
and II controlled substances is mandated by law and by international
treaty obligations. While aggregate production quotas are of primary
importance to large manufacturers, their impact upon small entities is
neither negative nor beneficial. Accordingly, the Deputy Administrator
has determined that this action does not require a regulatory
flexibility analysis.
Dated: July 19, 1995.
Stephen H. Greene,
Deputy Administrator.
[FR Doc. 95-18407 Filed 7-26-95; 8:45 am]
BILLING CODE 4410-09-M